In 2010, Thea Cacchioni testified before the US Food and Drug Administration against
flibanserin, a drug proposed to treat low sexual desire in women, dubbed by the media the “pink …

This paper seeks to illuminate the interactions of medics and other healthcare practitioners
with women’s bodies by looking at intervention in the area of women’s sexual problems or ‘…

It is increasingly taken for granted that `successful heterosexuality' is contingent upon
having a `normal' and `healthy' sex life. The recent popularity of the diagnostic label `Female …

The medicalization of women's sexual problems under the overall rubric of female sexual
dysfunction (FSD) has been thoroughly critiqued by feminist scholars, health practitioners, and …

This special issue grows out of the need to bring into focus the historical and sociocultural
contextualization of sex to the sexological community. The specific focus is on analyzing how …

Adding to a small but growing feminist literature, this article critically examines popular,
contemporary American sex manuals from a feminist social constructionist perspective, focusing …

Beginning in the late nineteenth century, western science, medicine, and the emergent fields
of psychiatry and sexology began to supersede custom and religion as the authorities on …

Sexuopharmaceutical drugs and the industry that surrounds them emerged following the
blockbuster success of Viagra in the late 1990s. This was an opportune social and economic …

The medicalization of the human condition is well understood within the sociological literature,
and women’s bodies have been particularly ripe targets for therapeutic treatment. Indeed, …

In 2010, The New View Campaign compiled 27 counter-narratives to present evidence that
challenged the perceived value and need for Flibanserin, a drug proposed to treat ‘…